13-valent Pneumococcal Conjugate Vaccine

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Pneumococcal Vaccines

Conditions

Pneumococcal Vaccines

Trial Timeline

Jun 1, 2007 → Sep 1, 2008

NCT ID

NCT00464945

About 13-valent Pneumococcal Conjugate Vaccine

13-valent Pneumococcal Conjugate Vaccine is a phase 3 stage product being developed by Pfizer for Pneumococcal Vaccines. The current trial status is completed. This product is registered under clinical trial identifier NCT00464945. Target conditions include Pneumococcal Vaccines.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05329259	Approved	Completed	Oct 6, 2022	Nov 30, 2022	Pneumococcal Disease
NCT03571607	Phase 3	Completed	Jul 12, 2018	Nov 16, 2018	Pneumococcal Infections
NCT02034877	Approved	Completed	Aug 1, 2014	Jul 1, 2015	Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC
NCT01026038	Phase 3	Completed	Apr 1, 2010	Nov 1, 2010	13-valent Pneumococcal Vaccine
NCT00963235	Phase 3	Completed	Nov 1, 2009	May 1, 2012	HIV Infections
NCT00708682	Phase 3	Completed	Jul 1, 2008	May 1, 2010	Vaccines, Pneumococcal
NCT00500357	Phase 3	Completed	Nov 1, 2007	Jan 1, 2010	Vaccines, Pneumococcal Conjugate Vaccine
NCT00452452	Phase 3	Completed	Jul 1, 2007	Mar 1, 2008	Pneumococcal Infections
NCT00464945	Phase 3	Completed	Jun 1, 2007	Sep 1, 2008	Pneumococcal Vaccines
NCT00269672	Phase 2	Completed	Sep 1, 2005	Feb 1, 2007	Vaccines, Pneumococcal Conjugate Vaccine

Competing Products

20 competing products in Pneumococcal Vaccines

See all competitors

Product	Company	Stage	Hype Score
V116 + PPSV23	Merck	Phase 3	77
V114 + QIV + Matching Placebo for V114	Merck	Phase 3	77
V114 + Prevnar 13™ + PNEUMOVAX™23	Merck	Phase 3	77
V114 Lot 1 + V114 Lot 2 + Prevnar 13™	Merck	Phase 2	52
PNEUMOVAX™ 23	Merck	Approved	85
Pneumococcal Vaccine, Polyvalent (23-valent)	Merck	Phase 3	77
V114 + Prevnar 13™ + PNEUMOVAX™23	Merck	Phase 3	77
V114 + Prevnar 13®	Merck	Phase 3	77
V114 Medium Dose + V114 High Dose + V114 Medium Dose with Alternative Carrier Protein + V114 High Dose with Alternative Carrier Protein + Prevnar 13™	Merck	Phase 1/2	41
V116 + PPSV23	Merck	Phase 3	77
V114	Merck	Phase 3	77
Prevnar 13™ + V114 + RotaTeq™ + Pentacel™ + RECOMBIVAX HB™ + HIBERIX™ + M-M-R™ II + VARIVAX™	Merck	Phase 3	77
V114 + Prevnar 13®	Merck	Phase 3	77
Pneumococcal Conjugate Vaccine (V114) + PNEUMOVAX® 23 + PREVNAR 13®	Merck	Phase 2	52
V114-A + V114-B + Prevnar 13®	Merck	Phase 2	52
V116 + Pneumovax™23	Merck	Phase 1/2	41
V114 + Prevnar 13™	Merck	Phase 3	77
V114 + Prevnar 13™	Merck	Phase 2	52
Simultaneous administration of Pneumovax NP® and Fluvic HA syringe® + Sequential administration of Pneumovax NP® and Fluvic HA syringe®	Merck	Approved	85
21-valent pneumococcal conjugate vaccine	Merck	Approved	85

Other Products from Pfizer